Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report)'s stock had its "buy" rating reiterated by equities researchers at HC Wainwright in a research note issued to investors on Friday, Benzinga reports. They presently have a $55.00 price target on the stock. HC Wainwright's target price points to a potential upside of 123.76% from the stock's previous close.
BCYC has been the subject of several other research reports. Needham & Company LLC restated a "buy" rating and issued a $43.00 target price on shares of Bicycle Therapeutics in a report on Wednesday, April 10th. Canaccord Genuity Group restated a "buy" rating and set a $60.00 price objective on shares of Bicycle Therapeutics in a research report on Wednesday, February 21st. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $46.86.
View Our Latest Stock Analysis on BCYC
Bicycle Therapeutics Stock Down 0.4 %
BCYC traded down $0.11 during trading hours on Friday, hitting $24.58. 324,430 shares of the company's stock were exchanged, compared to its average volume of 373,722. Bicycle Therapeutics has a 12-month low of $12.54 and a 12-month high of $28.91. The firm has a 50 day moving average of $24.03 and a 200 day moving average of $19.44. The firm has a market cap of $738.38 million, a P/E ratio of -4.79 and a beta of 0.90. The company has a current ratio of 8.08, a quick ratio of 8.08 and a debt-to-equity ratio of 0.08.
Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last announced its earnings results on Thursday, May 2nd. The company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($1.25) by $0.63. Bicycle Therapeutics had a negative net margin of 669.72% and a negative return on equity of 57.80%. The firm had revenue of $19.53 million for the quarter, compared to the consensus estimate of $6.06 million. The firm's revenue was up 298.9% on a year-over-year basis. Analysts predict that Bicycle Therapeutics will post -5.2 EPS for the current fiscal year.
Insider Buying and Selling
In related news, CEO Kevin Lee sold 3,158 shares of the firm's stock in a transaction that occurred on Wednesday, April 3rd. The shares were sold at an average price of $23.81, for a total value of $75,191.98. Following the sale, the chief executive officer now directly owns 387,270 shares of the company's stock, valued at $9,220,898.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last three months, insiders have sold 5,312 shares of company stock valued at $126,139. Insiders own 10.20% of the company's stock.
Institutional Trading of Bicycle Therapeutics
Hedge funds have recently made changes to their positions in the company. PDS Planning Inc acquired a new stake in shares of Bicycle Therapeutics during the first quarter worth approximately $210,000. China Universal Asset Management Co. Ltd. grew its position in shares of Bicycle Therapeutics by 71.4% during the first quarter. China Universal Asset Management Co. Ltd. now owns 6,859 shares of the company's stock worth $171,000 after buying an additional 2,858 shares in the last quarter. Pinnacle Associates Ltd. acquired a new stake in shares of Bicycle Therapeutics during the first quarter worth approximately $1,994,000. Woodstock Corp grew its position in shares of Bicycle Therapeutics by 16.3% during the first quarter. Woodstock Corp now owns 24,981 shares of the company's stock worth $622,000 after buying an additional 3,502 shares in the last quarter. Finally, PNC Financial Services Group Inc. acquired a new stake in shares of Bicycle Therapeutics during the fourth quarter worth approximately $137,000. Hedge funds and other institutional investors own 86.15% of the company's stock.
About Bicycle Therapeutics
(
Get Free Report)
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Bicycle Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicycle Therapeutics wasn't on the list.
While Bicycle Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
